Coca-Cola and Johnson & Johnson Report Mixed Financial Results Amid Dividend Streaks
Coca-Cola reported a 14% growth in Zero Sugar unit case volume for 2025, despite a $960M BODYARMOR impairment and a 7% revenue decline in Asia Pacific. Johnson & Johnson saw strong growth in its oncology drugs, with DARZALEX and TREMFYA revenue rising 22.5% and 68.3% respectively, but faced a 59.7% decline in STELARA due to biosimilar competition. Both companies maintain long dividend streaks but face different challenges in sustaining growth.
Topics: Coca-Cola consumer goods dividend growth dividend stocks financial performance Johnson & Johnson pharmaceuticals